Haemonetics price target lowered to $90 from $115 at Mizuho
Mizuho lowered the firm’s price target on Haemonetics (HAE) to $90 from $115 and keeps an Outperform rating on the shares post the earnings ...
Haemonetics downgraded to Underperform from Neutral at BofA
BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue ...
Yahoo Finance3d
Haemonetics (NYSE:HAE) Misses Q4 Revenue Estimates
Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per ...